The Medical Letter on Drugs and Therapeutics
Lisdexamfetamine dimesylate (Vyvanse) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Lisdexamfetamine dimesylate (Vyvanse – Shire), a prodrug in which d-amphetamine is covalently bonded to L-lysine, has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-12 years old. It was designed to have less potential than amphetamine itself for abuse, diversion or overdose toxicity.1,2 Like methylphenidate and amphetamines, lisdexamfetamine is a Schedule II controlled substance.

PHARMACOKINETICS — Lisdexamfetamine dimesylate is converted to d-amphetamine and L-lysine by enzymatic hydrolysis. Peak plasma concentrations of d-amphetamine after a 50-mg oral dose of lisdexamfetamine are about the same as those after a 30-mg oral dose of immediate-release d-amphetamine. Only minimal amounts of d-amphetamine are released when the drug is administered parenterally.

CLINICAL STUDIES — A randomized clinical trial ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lisdexamfetamine dimesylate (Vyvanse) for ADHD
Article code: 1265b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian